What to Do When UnitedHealthcare Denies Wegovy: Appeal Strategy

Introduction

UnitedHealthcare processes pharmacy benefits through OptumRx, which is the same company under the UnitedHealth Group umbrella. That means a Wegovy® denial comes back as an OptumRx adverse determination, and the level-1 appeal goes to OptumRx, not UnitedHealthcare directly.

The denial reasons fall into a predictable pattern: prior authorization criteria not met, step therapy required (usually a less expensive agent first), BMI threshold not satisfied, weight-loss drug carve-out by the employer, or missing documentation of a structured weight management program. Each has a specific counter that can be submitted on appeal.

CMS data from 2023 puts the overturn rate at roughly 41 percent for commercial denials when patients file a level-1 internal appeal with new clinical documentation. UnitedHealthcare appeals specifically have gained use after the SELECT trial (Lincoff et al. 2023, NEJM) showed 20 percent reduction in major adverse cardiovascular events, and the FDA approved Wegovy for cardiovascular risk reduction in March 2024. The CV indication is now a separate coverage pathway on most UHC plans.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Does UnitedHealthcare Deny Wegovy?

Five denial codes account for roughly 85 percent of UHC Wegovy rejections. The codes are PA-NOT-MET (PA criteria missing), NF (non-formulary), STEP-REQ (step therapy required), BMI-NOT-MET (BMI below threshold), and EMP-EXCL (employer carve-out for weight-loss drugs).

Quick Answer: UnitedHealthcare processes Wegovy through OptumRx; the level-1 appeal goes to OptumRx first

Read your OptumRx denial letter and find the reason code. The wording sits near a phrase reading “reason for adverse determination.” The appeal strategy depends entirely on which code applies.

An employer carve-out cannot be appealed because the benefit design comes from the plan document. Every other code can be overturned with the right documentation. The easiest to overturn is “medical necessity not established,” addressed by submitting chart notes, BMI history, and prior weight-loss attempts.

What Is UnitedHealthcare’s 2026 Prior Authorization for Wegovy?

UHC’s 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.

The cardiovascular indication added in 2024 has separate, looser criteria: established CVD (prior MI, ischemic stroke, or symptomatic PAD) plus BMI of 27 or higher. The 6-month lifestyle program is typically waived under the CV pathway.

A common single fix: most denials come from missing chart notes proving the 6-month weight management program. If your prescriber didn’t submit those notes with the PA, that’s the most likely reason.

How Do I File a Level-1 Internal Appeal with UnitedHealthcare?

You have 180 days from the denial date to file a level-1 internal appeal. The submission goes to OptumRx at the address on the denial letter, typically a PO Box in Schaumburg, Illinois or Irvine, California depending on plan.

The appeal packet should include a signed appeal letter from you, a Letter of Medical Necessity signed by your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program (dietitian visits, commercial program receipts, or primary care counseling notes), and prior medication trials with dates and outcomes.

OptumRx has 30 days to respond on a standard appeal and 72 hours on an expedited appeal. Expedited appeals require prescriber attestation that delay would seriously jeopardize health. Reasonable triggers include established CVD, uncontrolled type 2 diabetes, or severe OSA.

What Should the Letter of Medical Necessity Say?

The LMN is the single most important document. It should be on prescriber letterhead, signed and dated, and limited to two pages. OptumRx reviewers spend about 6 minutes per appeal file on average.

Hit five points directly. First, current BMI and weight, plus BMI trend over 24 months. Second, every comorbidity that meets UHC criteria with ICD-10 codes. Third, prior weight-loss interventions with start dates, end dates, and reasons for discontinuation, including any GLP-1 trials, phentermine, Contrave, Qsymia, or commercial programs. Fourth, clinical rationale citing the STEP 1 trial (Wilding et al. 2021, NEJM) showing 14.9 percent weight loss at 68 weeks, and SELECT (Lincoff et al. 2023, NEJM) showing 20 percent MACE reduction. Fifth, a clear statement that lifestyle modifications alone have not produced sustained clinical response.

Skip generic language. The LMN should read like a focused clinical case, not a literature review.

What Clinical Evidence Does UnitedHealthcare Respect?

OptumRx and UHC’s pharmacy and therapeutics committee reference specific trials when updating coverage policy. Citing those trials by name puts your appeal in their internal vocabulary.

For Wegovy, the strongest 2026 references are STEP 1 (Wilding et al. 2021, NEJM), STEP-HFpEF (Kosiborod et al. 2023, NEJM) for heart failure with preserved ejection fraction, SELECT (Lincoff et al. 2023, NEJM) for the cardiovascular indication, and FLOW (Perkovic et al. 2024, NEJM) showing 24 percent reduction in kidney disease progression and cardiovascular death.

Pick the two trials most relevant to your clinical situation. A focused appeal is more credible than a literature review.

Key Takeaway: 2026 UHC PA requires BMI of 30 or higher, or 27 with comorbidity, plus a 6-month documented weight management program

What If the First Appeal Is Denied?

You can file a level-2 internal appeal within 60 days of the level-1 denial, and pursue external review through your state insurance commissioner in parallel.

The level-2 internal appeal at UnitedHealthcare goes to a different reviewer, usually a board-certified physician. The packet can include the same documents plus a request for peer-to-peer review, where your prescriber speaks directly with UHC’s medical director. Peer-to-peer requests are granted on most appeals and significantly increase overturn rates.

External review through your state commissioner is independent of UnitedHealthcare and decisions are binding. The deadline is usually 4 months from the final internal denial. The independent review organization assigns a board-certified physician in endocrinology or obesity medicine for Wegovy reviews. The review costs nothing. Approval rates at external review run around 50 percent for prescription drug denials.

How Does the SELECT Cardiovascular Indication Change the Appeal?

If you have a history of MI, ischemic stroke, or symptomatic peripheral arterial disease, your appeal should lead with the cardiovascular indication, not the obesity indication. The FDA approved Wegovy for CV risk reduction in March 2024, and most UHC plans waive the 6-month lifestyle program requirement under that pathway.

The LMN should explicitly state “requested for cardiovascular risk reduction per FDA-approved indication based on SELECT trial.” Cite Lincoff et al. 2023 NEJM and note that SELECT enrolled 17,604 patients with established CVD and showed a hazard ratio of 0.80 for the primary MACE endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke).

That framing reroutes the review to a different criteria set with higher approval rates.

What If My UnitedHealthcare Plan Carves Out Weight-loss Drugs?

This is the hardest denial to overturn because the benefit design comes from the employer, not UnitedHealthcare’s medical policy. You have three practical options.

First, ask HR whether the carve-out applies to all indications or only the obesity indication. The cardiovascular indication may be covered separately on some self-funded plans. Second, request a formulary exception based on medical necessity. Some self-funded plans allow exceptions for documented CVD or type 2 diabetes with proven intolerance to alternatives. Third, consider cash-pay options. Compounded semaglutide through a licensed telehealth provider like TrimRx can be a fraction of the brand-name price, and a free assessment quiz determines eligibility in a few minutes.

Brand-name Wegovy through Novo Nordisk’s NovoCare savings card can drop the cost to as little as $0 for eligible commercially-insured patients, and the NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients.

How Long Does the Full Appeal Process Take?

A standard level-1 internal appeal takes 30 days. A level-2 takes another 30 days. External review is usually 45 days but can be expedited to 72 hours with documented urgent medical need.

Full timeline if you exhaust every level: roughly 4 to 5 months from initial denial to a final external review decision. Expedited appeals can compress this to 10 to 14 days.

While appeals are pending, options include paying cash with a plan for retroactive reimbursement if the appeal succeeds, using the Wegovy savings card if eligible, or starting a personalized treatment plan with a compounded GLP-1 through a telehealth provider during the review window.

Bottom line: You have 180 days to file a level-1 internal appeal and 4 months for external review

FAQ

Can I Appeal a UHC Wegovy Denial Without My Doctor’s Help?

Possible but rare to succeed. The Letter of Medical Necessity from the prescriber carries clinical authority that a patient letter cannot match. Most prescribers will write one if you ask in writing and provide the denial letter.

Does UnitedHealthcare Cover Wegovy for Medicare Patients?

UHC Medicare Part D plans cover Wegovy only for the cardiovascular indication after the March 2024 CMS update. Coverage for weight loss alone is not available under Medicare. The PA requires established CVD with ICD-10 codes and BMI of 27 or higher.

Does UnitedHealthcare Require STEP Therapy with Phentermine or Contrave?

Some UHC plans require step therapy with phentermine, Contrave, or Qsymia before approving Wegovy. The requirement can be waived with documented contraindications. Phentermine is contraindicated with CVD and uncontrolled hypertension. Contrave is contraindicated with seizure disorders, uncontrolled hypertension, and chronic opioid use.

How Much Does Wegovy Cost with UHC Coverage?

With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans. High-deductible plans charge the full negotiated rate (around $900 to $1,000 per month) until the deductible is met. Without coverage, brand-name Wegovy lists at about $1,349 per month, with NovoCare savings and direct cash options.

Can I Switch to Compounded Semaglutide If the Appeal Fails?

Yes. Compounded semaglutide from a licensed 503A pharmacy is the same active ingredient as Wegovy, prescribed through telehealth platforms like TrimRx after a clinical assessment. Costs run roughly $199 to $399 per month depending on dose. Compounding is legal when prescribed for an individual patient based on clinical need.

What Documents Does OptumRx Want in a Wegovy Appeal?

A signed appeal letter from you, a Letter of Medical Necessity from your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program, and a complete list of prior weight-loss medication trials with dates and outcomes.

Can I Get an Expedited Appeal If I Have Type 2 Diabetes?

Yes, in most cases. Expedited appeals are granted when delay would seriously jeopardize health. Uncontrolled type 2 diabetes with elevated A1C, recent hypoglycemic events, or evidence of microvascular complications all support an expedited request. The prescriber must attest to urgency in writing.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.